A promising drug for immunotherapy of solid tumorsKey arguments in support of the idea
▪ Initial clinical data for CLN-619 are pending.
Investment thesis
Cullinan Therapeutics is a clinical-stage biopharmaceutical
company developing drugs for the treatment of cancer.
On 1 June, Cullinan Therapeutics will present data from a Phase I
clinical